Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

Clinical trial NCT03283371 · COMPLETED

Trial details

NCT number: NCT03283371
Sponsor: Biogen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Epilepsy, Focal Seizures, Partial Seizures

Start date: 2018-03-20
Primary completion: 2020-01-11
Enrollment: 67

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.